Skip to main content
Log in

HPLC Method for Determination of 3,4-Diaminopyridine in the Presence of Related Substances and Degradation Products Formed Under Stress Conditions

  • Published:
Chromatographia Aims and scope Submit manuscript

Abstract

3,4-Diaminopyridine is used to treat some symptoms met in Lambert Eaton myasthenia syndrome. It was shown efficient to reduce a form of variable muscle weakness and fatigability typical of the disease and correlated to a block of acetylcholine release. A high performance liquid chromatographic method for the determination of 3,4-diaminopyridine in the presence of related substances and its degradation products is described. The method is based on the use of a C18 bonded phase column and a mobile phase composed of 10 volumes of acetonitrile and 90 volumes of an aqueous solution containing 1 g L−1 sodium octanesulfonate and 0.77 g L−1 ammonium acetate. The pH of the aqueous solution was adjusted to 1.9 with trifluoracetic acid. All peaks are eluted in <40 min. The method was demonstrated to be precise, accurate and specific even though a major part of the drug is decomposed. The results indicate that the proposed method could be used in stability assays.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Lundh H, Nilsson O, Rosén I, Johansson S (1993) Acta Neurol Scand 88:136–40

    Article  CAS  Google Scholar 

  • McEvoy KM, Windebank AJ, Daube JR, Low PA N. (1989) Engl J Med 32:567–71

    Google Scholar 

  • Lundh H, Nilsson O, Rosén I (1990) Progr Brain Res 8:63–70

    Google Scholar 

  • Sanders DB, Howard JF, Massey JM (1993) Ann, NY Acad Sci 68:88–90

    Google Scholar 

  • Bevers CT, Anderson PA, Leslie J, Panitch HS, Dhib-Jalbut S, Kahn OA et al. (1996) Neurology 4:457–62

    Google Scholar 

  • Lundh H, Nilsson O, Rosén I (1984) Neurology 3:324–30

    Google Scholar 

  • Leslie J. Bever C.T (1989) J Chromatogr 49:14–22

    Google Scholar 

  • Kamali F. Nicholson EJ (1995) J Pharm Biomed Anal 1:91–4

    Google Scholar 

  • Van der Horst A, de Goede PN, Van Dieman HA, Polman CH, Martens HJ (1992) J Chromatogr 57:66–9

    Google Scholar 

  • Goulay-Dufay S, Do B, LeHoang MD, Raust JA, Graffard H, Guyon F, Pradeau D (2004) J Chromatogr B 802 2:61–6

    Google Scholar 

  • Benzhiane H, Simon L, Carde A, Delacour H, Gentes P, Edouard B, Ghenname S, Flocard F (2003) Ann Pharm Fr 61 6:18–24

    Google Scholar 

  • ICH (Q1AR) (2000) Stability testing of new drug substances and products. International Conference on Harmonisation, IFPMA, Geneva

  • ICH (Q2A) (1994) Note for guidance on validation of analytical methods: definitions and terminology. International Conference on Harmonisation, IFPMA, Geneva

    Google Scholar 

  • ICH (Q2B) (1996) Note for guidance on validation of analytical procedure: methodology. International Conferences on Harmonisation, IFPMA, Geneva

    Google Scholar 

  • ICH (Q3A) (2003) Impurities in new drug substances. International Conferences on Harmonisation, IFPMA, Geneva

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to B. Do.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Do, B., Goulay-Dufaÿ, S., Hoang, M.D.L. et al. HPLC Method for Determination of 3,4-Diaminopyridine in the Presence of Related Substances and Degradation Products Formed Under Stress Conditions. Chroma 63, 599–603 (2006). https://doi.org/10.1365/s10337-006-0821-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1365/s10337-006-0821-y

Keywords

Navigation